Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Visiongain publishes Allergic Rhinitis Drugs Market 2020-2030 report

This image opens in the lightbox

News provided by

Visiongain

28 Aug, 2020, 08:00 GMT

Share this article

Share toX

Share this article

Share toX

Forecasts by Sub-Markets (Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, Immunotherapy and Vaccines, Others), Intranasal Antihistamines (Dymista, Generic Intranasal Azelastine, Astepro, Patanase, Astelin, Others), Intranasal Corticosteroids (Flixonase/Flonase/Flonase OTC, Nasonex, Avamys/Veramyst, Rhinocort, Nasacort/Nasacort-OTC, Omnaris, Beconase/Beconaes AQ, Qnasl, Zetonna, Others), Oral Antihistamines (Allegra/Allegra-D/Allegra OTC, Claritin/Claritin OTC, Zyrtec/Zyrtec D, Xyzal, Clarinex, Allelock, Ebastel, Talion, Others), Immunotherapy and Vaccines (Staloral, Alutard SQ, Grazax/Grastek, Oralair, Ragwitek, Others), and Geography (North America, Latin America, Europe, Asia Pacific, MEA)

LONDON, Aug. 28, 2020 /PRNewswire/ -- Allergic Rhinitis Drugs–our new study reveals trends, R&D progress, and predicted revenues
Where is the Allergic Rhinitis Drugs market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 330+ page report provides 450+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Allergic Rhinitis Drugs Market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects

• In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, SWOT, and Porter's Fiver Forces Analysis), product profiles and commercial developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

To request sample pages from this report please email contactus@visiongain.com or refer to our website: https://www.visiongain.com/report/allergic-rhinitis-drugs-market-report-2020-2030/#download_sampe_div

Discover sales predictions for the world market and submarkets

Global Allergic Rhinitis Drugs Market by Sub-Markets

• Intranasal Antihistamines
• Dymista
• Generic Intranasal Azelastine
• Astepro
• Patanase
• Astelin
• Others

• Intranasal Corticosteroids
• Flixonase/Flonase/Flonase OTC
• Nasonex
• Avamys/Veramyst
• Rhinocort
• Nasacort/Nasacort-OTC
• Omnaris
• Beconase/Beconaes AQ
• Qnasl
• Zetonna
• Others

• Oral Antihistamines
• Allegra/Allegra-D/Allegra OTC
• Claritin/Claritin OTC
• Zyrtec/Zyrtec D
• Xyzal, Clarinex
• Allelock
• Ebastel
• Talion
• Others

• Immunotherapy and Vaccines
• Staloral
• Alutard SQ
• Grazax/Grastek
• Oralair
• Ragwitek
• Others

• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 17 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Belgium
• Switzerland
• Rest of Europe

Asia-Pacific
• Japan
• China
• India
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM

Middle East and Africa
• UAE
• Saudi Arabia
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Allergic Rhinitis Drugs Market, with a focus on this segment of these companies' operations. There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and India, China in particular, will continue to achieve high revenue growth to 2030.

Leading companies and the potential for market growth

Overall world revenue for Allergic Rhinitis Drugs Market will surpass $xyz billion in 2020, our work calculates. We predict strong revenue growth through to 2030.

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Allergic Rhinitis Drugs Market report helps you

In summary, our 330+ page report provides you with the following knowledge:

• Revenue forecasts to 2030 for Allergic Rhinitis Drugs Market, with forecasts for Intranasal Antihistamines, Intranasal Corticosteroids, Oral Antihistamines, Immunotherapy and Vaccines, Others, each forecasted at a global and regional level– discover the industry's prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2030 for 5 regional and 17 key national markets – See forecasts for the Allergic Rhinitis Drugs market in North America, Latin America, Europe, Asia-Pacific and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Argentina, Germany, France, UK, Italy, Spain, Belgium, Switzerland, China, India, Japan, UAE, Saudi Arabia, and South Africa.

• Prospects for established firms and those seeking to enter the market– including company profiles for Merck KGaA, Stallergenes Greer, AstraZeneca, Boehringer Ingelheim International GmbH, Bayer AG, Novartis AG, GSK, Johnson & Johnson, UCB S.A., Kyowa Hakko Kirin, ALK-Abelló A/S, and Sanofi involved in the Allergic Rhinitis Drugs Market.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

To request a report overview of this report please email contactus@visiongain.com or refer to our website: https://www.visiongain.com/report/allergic-rhinitis-drugs-market-report-2020-2030/

Did you know that we also offer a report add-on service? Email contactus@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

ALK-Abelló A/S
AstraZeneca
Bayer AG\
Boehringer Ingelheim International GmbH
GSK
Johnson & Johnson
Kyowa Hakko Kirin
Merck KGaA
Novartis AG
Sanofi
Stallergenes Greer
UCB S.A.

Organizations

American Academy of Allergy, Asthma and Immunology (AAAAI)
British Society for Allergy & Clinical Immunology (BSACI) [UK]
International Nurses Group In Immunodeficiencies
Japanese Ministry of Health, Labour and Welfare
Les Entreprises Du Médicament (Leem) [France]
National Development and Reform Commission (NDRC) [China]
National Pharmaceutical Pricing Authority (NPPA) [India]
PollenUK
The Pharmaceutical Research and Manufacturers of America (PhRMA)
The UK Health and Social Care Information Centre
US Food and Drug Administration (FDA)
World Allergy Organisation
World Health Organisation (WHO)

To see a report overview please e-mail contactus@visiongain.com 

RELATED REPORTS:

Nasal Drug Delivery Technology Market Forecast 2020-2030

Top 26 Asthma & COPD Companies 2020-2030

Global Asthma & COPD Therapies Market 2019-2029

Novel Coronavirus (COVID-19) Drugs in Development Market Forecast 2020-2030

Logo: https://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.